Jane Street Group LLC bought a new position in shares of Zymeworks Inc (NYSE:ZYME) in the 4th quarter, HoldingsChannel.com reports. The firm bought 76,803 shares of the company’s stock, valued at approximately $1,127,000.
Several other large investors have also added to or reduced their stakes in ZYME. Opaleye Management Inc. bought a new position in Zymeworks during the fourth quarter valued at approximately $1,541,000. Fosun International Ltd bought a new position in Zymeworks during the fourth quarter valued at approximately $1,030,000. Wells Fargo & Company MN boosted its stake in Zymeworks by 103.0% during the third quarter. Wells Fargo & Company MN now owns 89,794 shares of the company’s stock valued at $1,410,000 after buying an additional 45,560 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Zymeworks by 11.8% during the third quarter. Renaissance Technologies LLC now owns 376,800 shares of the company’s stock valued at $5,916,000 after buying an additional 39,800 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Zymeworks by 35.1% during the fourth quarter. Acadian Asset Management LLC now owns 113,399 shares of the company’s stock valued at $1,667,000 after buying an additional 29,468 shares during the last quarter. Hedge funds and other institutional investors own 28.37% of the company’s stock.
In related news, major shareholder Eli & Co Lilly sold 250,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 31st. The stock was sold at an average price of $16.00, for a total transaction of $4,000,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ali Tehrani sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, March 29th. The stock was sold at an average price of $16.24, for a total value of $48,720.00. The disclosure for this sale can be found here. 4.80% of the stock is owned by company insiders.
Zymeworks (NYSE:ZYME) last posted its quarterly earnings data on Wednesday, March 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.19. The business had revenue of $28.93 million during the quarter, compared to analyst estimates of $65.00 million. Zymeworks had a negative return on equity of 23.17% and a negative net margin of 68.95%. On average, sell-side analysts predict that Zymeworks Inc will post -2.37 earnings per share for the current fiscal year.
A number of equities analysts recently commented on the company. Zacks Investment Research lowered Zymeworks from a “buy” rating to a “hold” rating in a research note on Saturday. Raymond James set a $29.00 price target on Zymeworks and gave the company an “outperform” rating in a research note on Thursday, March 14th. TheStreet raised Zymeworks from a “d” rating to a “c-” rating in a research note on Friday, January 11th. Finally, ValuEngine raised Zymeworks from a “hold” rating to a “buy” rating in a research note on Monday, January 7th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $23.29.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://sportsperspectives.com/2019/04/02/jane-street-group-llc-invests-1-13-million-in-zymeworks-inc-zyme.html.
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer.
Further Reading: What is a trade deficit?
Want to see what other hedge funds are holding ZYME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zymeworks Inc (NYSE:ZYME).
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.